-
May 23, 2013
Boehringer Ingelheim says it will act promptly to resolve a series of manufacturing complaints highlighted by regulators in the USA concerning violations at its German headquarters
Full story
-
May 22, 2013
US spending on specialty prescription drugs - those used to treat chronic, complex diseases such as cancer, multiple sclerosis and rheumatoid arthritis - is projected to increase 67% by the end of 2015, say new forecasts.
Full story
-
May 22, 2013
Biogen Idec has filed a pegylated version of its blockbuster Avonex, called Plegridy, with the US Food and Drug Administration for relapsing forms of multiple sclerosis
Full story
-
May 15, 2013
US regulators have approved Bayer's Xofigo as a treatment for prostate cancer, just three months after it was assigned a priority review.
Full story
-
May 15, 2013
Shares in Seattle Genetics were on the rise yesterday as investors welcomed news that US regulators are to review extended use of Adcetris in two types of lymphoma.
Full story
-
May 14, 2013
US regulators have agreed to conduct an accelerated review of Janssen Research & Development's investigational hepatitis C drug simeprevir.
Full story
-
May 13, 2013
As expected, the US Food and Drug Administration has given the green light to GlaxoSmithKline and Theravance's Breo Ellipta for chronic obstructive pulmonary disease
Full story
-
May 10, 2013
The US Food and Drug Administration has given the green light to Novartis' Ilaris as a treatment for a serious form of childhood arthritis.
Full story
-
May 10, 2013
US regulators have issued a green light for Warner Chilcott's new oestrogen/progestin-based oral contraceptive, which is yet to be given an official trade name.
Full story
-
May 10, 2013
Total spending on US medicines fell 3.5% on a real per-capita basis in 2012, and the use of healthcare services overall declined for the second consecutive year, according to a new study from the IMS Institute for Healthcare Informatics.
Full story